Literature DB >> 8335938

Localization of an immunologically functional region of the streptococcal superantigen pepsin-extracted fragment of type 5 M protein.

B Wang1, P M Schlievert, A O Gaber, M Kotb.   

Abstract

Ten overlapping synthetic peptides, spanning the entire amino acid sequence of pepsin-extracted type 5 M protein, (pep M5), were used to delineate regions within this molecule that are important for the mitogenic activity of this streptococcal superantigen. Two of the overlapping peptides, SM5-8 and SM5-10, blocked the response of T cells to pep M5 in a dose-dependent manner. Neither peptide was toxic to T cells, but SM5-8 exhibited nonspecific inhibition of the T-cell response to either superantigen or polyclonal mitogens. In contrast, the inhibition by SM5-10 was pep M5-specific. Analysis of TCR V beta gene usage of the pep M5 response in the presence and absence of SM5-10 revealed that this peptide preferentially blocks the expansion of pep M5-specific V beta elements. The degree of inhibition of V beta expansion varied from one individual to the other, reflecting their TCR repertoire. SM5-10 did not significantly inhibit the response of T cells to other streptococcal superantigens. The data suggest that the region represented by SM5-10 of the pep M5 is important for superantigenic activity. In addition, the ability of this synthetic peptide to inhibit the response to pep M5 provides evidence that the mitogenic response is indeed mediated by this superantigen and is not a result of contamination with other streptococcal superantigens.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8335938

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  The prospect of vaccination against group A beta-hemolytic streptococci.

Authors:  Karen L Kotloff
Journal:  Curr Infect Dis Rep       Date:  2008-05       Impact factor: 3.725

Review 2.  Bacterial pyrogenic exotoxins as superantigens.

Authors:  M Kotb
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

Review 3.  Gram-positive bacterial superantigen outside-in signaling causes toxic shock syndrome.

Authors:  Amanda J Brosnahan; Patrick M Schlievert
Journal:  FEBS J       Date:  2011-05-19       Impact factor: 5.542

Review 4.  Pathogenesis of group A streptococcal infections.

Authors:  M W Cunningham
Journal:  Clin Microbiol Rev       Date:  2000-07       Impact factor: 26.132

5.  Molecular analysis of human cardiac myosin-cross-reactive B- and T-cell epitopes of the group A streptococcal M5 protein.

Authors:  M W Cunningham; S M Antone; M Smart; R Liu; S Kosanke
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

Review 6.  Molecular Mimicry, Autoimmunity, and Infection: The Cross-Reactive Antigens of Group A Streptococci and their Sequelae.

Authors:  Madeleine W Cunningham
Journal:  Microbiol Spectr       Date:  2019-07

7.  Identification of staphylococcal enterotoxin B sequences important for induction of lymphocyte proliferation by using synthetic peptide fragments of the toxin.

Authors:  M Jett; R Neill; C Welch; T Boyle; E Bernton; D Hoover; G Lowell; R E Hunt; S Chatterjee; P Gemski
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

8.  Mitogenicity of M5 protein extracted from Streptococcus pyogenes cells is due to streptococcal pyrogenic exotoxin C and mitogenic factor MF.

Authors:  K H Schmidt; D Gerlach; L Wollweber; W Reichardt; K Mann; J H Ozegowski; B Fleischer
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

Review 9.  Superantigens and pseudosuperantigens of gram-positive cocci.

Authors:  B Fleischer; D Gerlach; A Fuhrmann; K H Schmidt
Journal:  Med Microbiol Immunol       Date:  1995-05       Impact factor: 3.402

10.  Novel toxic shock syndrome toxin-1 amino acids required for biological activity.

Authors:  Amanda J Brosnahan; Matthew M Schaefers; William H Amundson; Mary J Mantz; Christopher A Squier; Marnie L Peterson; Patrick M Schlievert
Journal:  Biochemistry       Date:  2008-12-09       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.